CDK6 Amplification

CI-VAR-00000232Explore in graph →CIViC 1685

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioblastoma1
CDK6 Amplification	Palbociclib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12398 Preclinical experiments using patient-derived GBM cell lines were performed to examine efficacy of CDK4/6 inhibitor palbociclib. The cell line CCF-STTG1 that harbours CDK6 amplification was sensitive … (full text at CIViC) PMID 20354191 · Michaud et al., 2010 · Open in CIViC	civic
Estrogen Receptor-positive Breast Cancer1unmapped disease
CDK6 Amplification	Abemaciclib	Predictive	D	Does Not Support Resistance	4	submitted	EID4843 Inhibitors of CDK4/6 complex have advanced in clinic and have shown significant activity, particularly against tumors driven by the estrogen receptor (ER). Consecutively resistance to these agents has…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.